Last reviewed · How we verify
Ropivacaine, Ketorolac, adrenaline
At a glance
| Generic name | Ropivacaine, Ketorolac, adrenaline |
|---|---|
| Sponsor | University of Aarhus |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Opioid-Free Pain Protocol After Shoulder Arthroplasty (PHASE4)
- R.E.C.K vs Exparel in Robotic Nephrectomy (PHASE3)
- Use of Corticosteroid in Intraopertive Injections in Total Knee Replacement Surgery. (PHASE2, PHASE3)
- Prospective Opioid-Free AIS Fusion (PHASE4)
- Effect of RECK in Posterior Spinal Fusion (PHASE1, PHASE2)
- LIA vs. LIA + ACB-iPACK Block for Total Knee Arthroplasty (NA)
- Effects Of Intra-Operative Intra-Articular Cocktail Injection In Patella Open Reduction And Internal Fixation (PHASE4)
- Periarticular Bupivacaine + Meloxicam ER Solution Versus Standard Practice During Total Knee Arthroplasty (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Ropivacaine, Ketorolac, adrenaline CI brief — competitive landscape report
- Ropivacaine, Ketorolac, adrenaline updates RSS · CI watch RSS
- University of Aarhus portfolio CI